A recent meta-analysis reports that in patients with non-small cell lung cancer (NSCLC), the ERCC1 (rs11615), XRCC1 (X-ray repair cross complementing 1: rs25487, rs1799782) and XPD (xeroderma pigmentosum group D: rs13181) polymorphisms are predictive factors of effectiveness in response to chemotherapy based on platinum regimens22. Here, XRCC1 is linked to non-small cell lung carcinoma.